US4382080A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for treating and preventing bacterial infections
Assignee: Daiichi Pharmaceutical Co Ltd
•
Filing: 1981-05-11
•
Granted: 1983-05-03
•
Expires: 2001-05-11
Abstract
Abstract A method for treating and preventing bacterial infections which comprises administering a 6-O-acylmuramyl depeptide of the formula: ##STR1## wherein X represents a divalent residual group of an amino acid such as L-alanine, L-serine, L-valine, etc., Y represents a residual group of a middle to higher fatty acid having 10 to 60 carbon atoms and isoGln represents a residual group of isoglutamine, or a pharmaceutical composition containing a 6-O-acylmuramyl dipeptide of the formula(I) as an active ingredient to a patient afflicted therewith.
Inventors
- 👤 Tetsuo Shiba
- 👤 Yuichi Yamamura
- 👤 Shozo Kotani
- 👤 Osamu Nagase
- 👤 Hidemasa Ogawa
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 04:59
CPC Classifications
C; C07; C07K; C07K9/00; C07K9/001; C07K9/005; A; A61; A61P; A61P31/00; A61P31/04
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
52 words
A method for therapeutic treatment and/or prophylaxis of bacterial infections which comprises administering an anti-bacterial infection therapeutically effective amount or an anti-bacterial infection prophylactic effective amount of a compound selected from the group consisting of 6-O-stearoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine, 6-O-stearoyl-N-acetylmuramyl-L-seryl-D-isoglutamine, 6-O-stearoyl-N-acetylmuramyl-L-valyl-D-isoglutamine, and 6-O-docosanoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine to a patient who does or does not have a bacterial infection.
Claim 2
Independent Claim
52 words
A method for therapeutic treatment and/or prophylaxis of bacterial infections which comprises administering an anti-bacterial infection therapeutically effective amount or an anti-bacterial infection prophylactic effective amount of a compound selected from the group consisting of 6-O-stearoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine, 6-O-stearoyl-N-acetylmuramyl-L-seryl-D-isoglutamine, 6-O-stearoyl-N-acetylmuramyl-L-valyl-D-isoglutamine, and 6-O-docosanoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine to a patient who does or does not have a bacterial infection.
Claim 3
Dependent Claim
27 words
The method of claim 1 wherein said compound administered is administered in an effective dose which is effective to control E. coli, P. aeruginosa or K. pneumoniae.
Claim 4
Dependent Claim
19 words
The method of claim 2 wherein said compound is administered in an effective dose effective to control C. albicans.
Claim 5
Dependent Claim
24 words
The method of claim 1 wherein said compound is administered to said patient prior to the time when said patient exhibits a bacterial infection.
Claim 6
Dependent Claim
23 words
The method of claim 1 wherein said compound is administered to said patient prior to and after said patient exhibits a bacterial infection.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-05-02 | 1986-11-01 | 1987-05-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-05-02 | 1990-11-01 | 1991-05-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-05-02 | 1994-11-01 | 1995-05-03 | $7700.00 | Window Closed / Lapsed |